Madrigal Pharmaceuticals

At Madrigal, patients are at the heart of everything we do. Becky’s journey with MASH highlights the importance an early diagnosis. Thank you to Becky and the broader MASH community who are fighting every day to improve the lives of people affected by this serious liver disease.

Kim was given two years to live after an unexpected diagnosis of end-stage cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Following a life-saving liver transplant, her story underscores the important role patient advocacy and education can play in battling MASH.

Becky's MASH (metabolic dysfunction-associated steatohepatitis) diagnosis was a shocking revelation, echoing the painful memories of her brother's lost battle with liver disease. She shares her journey to raise awareness and navigate the emotional challenges of MASH, including confusion, isolation, and regret over lost time.

As #TLM25 comes to a close, we’re grateful for the opportunity to connect with so many HCPs, advocates, and patients who share our commitment to advancing care in MASH. Thank you for the incredible engagement, insights, and collaboration — here’s to continued progress, partnership, and purpose! American Association for the Study of Liver Diseases (AASLD)

Reflecting on the Patient Advocacy Listening Session and advocacy panel at the American Association for the Study of Liver Diseases (AASLD)'s #TLM25, I am grateful for the opportunity to participate in discussions with patients, advocates and clinicians whose voices guide us at Madrigal Pharmaceuticals. While we’ve made tremendous progress as an industry, there’s still work we can all do to help uplift and empower those living with liver diseases. A big shoutout to everyone who participated—your experiences, stories and guidance continue to inspire us to make a meaningful difference for the community.